【摘要】：目的:研究經(jīng)皮冠狀動脈介入治療(PCI)術(shù)后急性冠脈綜合征(ACS)患者替格瑞洛治療后血尿酸(SUA)變化及其對炎癥因子的影響,并與氯吡格雷比較,探討替格瑞洛抗炎效應(yīng)。方法:行PCI術(shù)后ACS患者162例,隨機均分為氯吡格雷對照組和替格瑞洛治療組(每組各81例),每組均連續(xù)用藥3個月,比較分析2組治療前后SUA、炎癥因子如超敏C-反應(yīng)蛋白(hsCRP)、白細胞介素-6(IL-6)和可溶性CD40配體(sCD40L)水平;與基線SUA水平比較,根據(jù)治療后SUA變化,2組再各分為SUA升高組和SUA降低組,分析SUA與炎癥因子相關(guān)性及SUA變化對炎癥因子的影響。結(jié)果:氯吡格雷對照組治療前后SUA水平變化無統(tǒng)計學(xué)意義(P0.05),而治療后替格瑞洛治療組的SUA水平較基線顯著增高(P0.05);兩組炎癥因子水平均較治療前明顯改善(P0.05),且與氯吡格雷對照組相比,替格瑞洛治療組炎癥因子水平改善更顯著(P0.05);氯吡格雷對照組中SUA升高組與SUA降低組炎癥因子水平變化無統(tǒng)計學(xué)意義(P0.05),而替格瑞洛治療組治療后,SUA與炎癥因子顯著正性相關(guān),SUA升高組炎癥因子水平均較SUA降低組顯著增高(P0.05)。結(jié)論:PCI術(shù)后ACS患者替格瑞洛治療后SUA增高明顯,高水平SUA可能促進炎癥因子產(chǎn)生,但其炎癥因子水平改善作用比氯吡格雷更顯著,提示替格瑞洛較氯吡格雷的抗炎作用明顯增強,高水平SUA對炎癥因子的影響可能不足以抵消其本身較強的抗炎效應(yīng)。
[Abstract]:Objective: to study the changes of serum uric acid (SUA) and its effect on inflammatory factors in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI), and compare with clopidogrel. To investigate the anti-inflammatory effect of tigrillo. Methods: 162 patients with ACS after PCI were randomly divided into two groups: clopidogrel control group and tigrilol treatment group (81 cases in each group). SUA, was compared before and after treatment in each group for 3 months. The levels of inflammatory factors such as (hsCRP), interleukin-6 (IL-6) and soluble CD40 ligand (sCD40L) were detected. Compared with baseline SUA, according to the changes of SUA after treatment, the two groups were divided into two groups: the SUA increased group and the SUA decreased group. The correlation between SUA and inflammatory factors and the effect of SUA changes on the inflammatory factors were analyzed. Results: there was no significant change of SUA level in clopidogrel control group before and after treatment (P0.05), but the SUA level of tigrilol group was significantly higher than that of baseline group (P0.05). Compared with clopidogrel control group, the level of inflammatory factors in tigrello group was significantly improved (P0.05). In clopidogrel control group, there was no significant difference in the level of inflammatory factors between the elevated SUA group and the decreased SUA group (P0.05). However, after treatment with tigrilol, SUA was positively correlated with inflammatory factors. The level of inflammatory cytokines in SUA increased significantly compared with that in SUA group (P 0.05). Conclusion: the level of SUA in patients with ACS after PCI is significantly higher than that of clopidogrel. The high level of SUA may promote the production of inflammatory factors, but the effect of improving the level of inflammatory factors is more significant than that of clopidogrel. The results suggest that tigrilol has stronger anti-inflammatory effect than clopidogrel, and the effect of high level of SUA on inflammatory factors may not be enough to counteract its strong anti-inflammatory effect.
【作者單位】： 運城護理職業(yè)學(xué)院臨床部;山西醫(yī)科大學(xué)第二醫(yī)院心內(nèi)科;
【分類號】：R541.4

【參考文獻】

相關(guān)期刊論文 前6條

1 史香芬;劉帥兵;王肖栻;孫志勇;;替格瑞洛在中國健康男性志愿者中的藥動學(xué)及藥效學(xué)研究[J];中國醫(yī)院藥學(xué)雜志;2016年21期

2 朱勇;張美春;高孟秋;孫艷霞;胡俊靈;何成龍;王崇輝;李玉明;;替格瑞洛與氯吡格雷對冠心病患者冠狀動脈介入術(shù)后炎癥因子的影響[J];中國臨床藥理學(xué)雜志;2016年14期

3 張士慶;朱永宏;;替格瑞洛引起血尿酸升高機制及治療策略[J];中國循證心血管醫(yī)學(xué)雜志;2016年04期

4 張陽陽;陳魁;;替格瑞洛與氯吡格雷對急性STEMI患者急診PCI術(shù)后炎癥因子的影響[J];醫(yī)學(xué)與哲學(xué)(B);2014年09期

5 金辰;李衛(wèi);袁晉青;楊躍進;;冠狀動脈支架內(nèi)血栓的成因和防治[J];心血管病學(xué)進展;2013年05期

6 韓雅玲;;中國經(jīng)皮冠狀動脈介入治療指南2012(簡本)[J];中華危重癥醫(yī)學(xué)雜志(電子版);2012年03期

【共引文獻】

相關(guān)期刊論文 前10條

1 魏洪杰;石俊婷;李星星;康美麗;;冠脈支架術(shù)后氯吡格雷抵抗患者抗血小板藥物療效研究[J];臨床和實驗醫(yī)學(xué)雜志;2017年16期

2 曹莉;邊云飛;;替格瑞洛對PCI術(shù)后急性冠脈綜合征患者血尿酸影響及其抗炎效應(yīng)[J];中國醫(yī)院藥學(xué)雜志;2017年15期

3 歐武華;歐陽武雄;;新型抗血栓藥物替格瑞洛對PCI術(shù)后患者出血風(fēng)險的評估[J];實用藥物與臨床;2017年07期

4 劉潔;劉勉;陳云爽;;造影劑腎病高危因素及診治的相關(guān)研究進展[J];解放軍醫(yī)藥雜志;2017年07期

5 樊壘壘;楊威;席宏巍;李曉玲;王幼平;;冠脈搭橋術(shù)11年后再發(fā)心絞痛介入治療1例[J];中國現(xiàn)代醫(yī)生;2017年18期

6 張陽;宋滄桑;李興德;周興龍;;PCI術(shù)后患者服用氯吡格雷依從性調(diào)查分析[J];中國藥物評價;2017年03期

7 何曉雷;楊麗;孫穩(wěn);;替格瑞洛與氯吡格雷治療冠心病心肌缺血的臨床療效對比[J];中國生化藥物雜志;2017年06期

8 鞏聿芬;;循證護理在冠心病患者介入治療中的療效[J];健康之路;2017年05期

9 呂文君;;替格瑞洛聯(lián)合復(fù)方丹參滴丸在冠心病患者中的臨床應(yīng)用[J];中國繼續(xù)醫(yī)學(xué)教育;2017年13期

10 劉銳;葉傳冬;雷寧寧;莫云秋;;活血化瘀中藥防治PCI術(shù)后冠脈再狹窄Meta分析[J];遼寧中醫(yī)藥大學(xué)學(xué)報;2017年05期

【二級參考文獻】

相關(guān)期刊論文 前10條

1 ;急性ST段抬高型心肌梗死診斷和治療指南[J];中華心血管病雜志;2015年05期

2 李秀芬;葛振嶸;許力舒;姜述斌;帕爾哈提·吐爾遜;;替格瑞洛聯(lián)合小劑量替羅非班對急性非ST段抬高心肌梗死患者纖維蛋白原的影響[J];中華老年心腦血管病雜志;2015年04期

3 李云妹;莫均榮;陳曉輝;田朝偉;劉炳煩;江慧琳;林s鉅，

本文編號：2334739